Published in BMC Nephrology, the Phase I human clinical trial, conducted in partnership with Massachusetts General Hospital, enabled the FDA approval of an Investigational New Drug application for Basis and the AKI Phase II trial.
Acute Kidney Injury (AKI) Phase II
Initiated at Mayo Clinic, the human clinical trial will evaluate the efficacy of Basis for the prevention of AKI in patients that have undergone a cardiac surgery; primary study completion date October 2023.
Completed and published in the International Journal of Toxicology. The results showed that Elysium’s proprietary nicotinamide riboside (NR-E) has a superior safety profile to all other consumer NR products.
Initiated in collaboration with Duke Clinical Research Institute, this clinical trial will evaluate correlations between epigenetic aging (measured using Index) and NAD+ levels in healthy adults; expected completion 2022/2023.
Completed study to assess the effects of nicotinamide riboside (NR) and pterostilbene (PT) on UV-induced swelling, immunosuppression, and markers of DNA damage in mice; study will be published in 2022 or 2023.
Working in collaboration with the Spanish Foundation for ALS Research (FUNDELA), the results of this pilot study showed evidence the experimental therapeutic EH301 can be used in treatment of amyotrophic lateral sclerosis (ALS).
Initiated with partners at Haukeland University Hospital, this human clinical trial will evaluate the efficacy of the experimental therapeutic EH301 for the treatment of amyotrophic lateral sclerosis (ALS); expected completion date December 2022.
Initiated with partners at the University of Copenhagen and funded by a grant from the Danish Government, this clinical trial will evaluate the effect of Elysium’s proprietary nicotinamide riboside (NR-E) on clinical outcomes in elderly patients with COPD. Expected completion date is late 2022.